In pancreatic cancer, a growing body of research indicates that the activation of SREBP2 leads to alterations in cholesterol metabolism, thereby enhancing cancer cell resistance to apoptosis and promoting tumorigenesis and progression. The gene discussed is SREBF2; the disease is familial pancreatic carcinoma.